A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Isatuximab (Primary) ; Carfilzomib
- Indications Multiple myeloma
- Focus Adverse reactions
- 15 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 15 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated